These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 26115884)

  • 1. Single nucleotide polymorphisms of the EpCAM-coding gene TACSTD1 in patients with ovarian cancer and their potential translational aspects.
    Heubner M; Wimberger P; Kasimir-Bauer S; Singer BB; Ruf P; Kimmig R; Siffert W
    Arch Gynecol Obstet; 2015 Dec; 292(6):1367-72. PubMed ID: 26115884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A non-synonymous polymorphism Thr115Met in the EpCAM gene is associated with an increased risk of breast cancer in Chinese population.
    Jiang L; Zhang C; Li Y; Yu X; Zheng J; Zou P; Li Y; Bin X; Lu J; Zhou Y
    Breast Cancer Res Treat; 2011 Apr; 126(2):487-95. PubMed ID: 20683652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional polymorphism in the EpCAM gene is associated with occurrence and advanced disease status of cervical cancer in Chinese population.
    Hu M; Jian L; Zhang L; Zheng J; You Y; Deng J; Li H; Zhou Y
    Mol Biol Rep; 2012 Jul; 39(7):7303-9. PubMed ID: 22322561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphisms of EpCAM gene and prognosis for non-small-cell lung cancer in Han Chinese.
    Yang Y; Fei F; Song Y; Li X; Zhang Z; Fei Z; Su H; Wan S
    Cancer Sci; 2014 Jan; 105(1):89-96. PubMed ID: 24304228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer.
    Ruf P; Gires O; Jäger M; Fellinger K; Atz J; Lindhofer H
    Br J Cancer; 2007 Aug; 97(3):315-21. PubMed ID: 17622246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab.
    Seeber A; Braicu I; Untergasser G; Nassir M; Fong D; Botta L; Gastl G; Fiegl H; Zeimet A; Sehouli J; Spizzo G
    Oncotarget; 2015 Sep; 6(28):25017-23. PubMed ID: 26296970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble EpCAM levels in ascites correlate with positive cytology and neutralize catumaxomab activity in vitro.
    Seeber A; Martowicz A; Spizzo G; Buratti T; Obrist P; Fong D; Gastl G; Untergasser G
    BMC Cancer; 2015 May; 15():372. PubMed ID: 25947366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The AA genotype of a L1C G842A polymorphism is associated with an increased risk for ovarian cancer.
    Heubner M; Wimberger P; Kasimir-Bauer S; Otterbach F; Kimmig R; Siffert W
    Anticancer Res; 2009 Aug; 29(8):3449-52. PubMed ID: 19661372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microparticles from ovarian carcinomas are shed into ascites and promote cell migration.
    Press JZ; Reyes M; Pitteri SJ; Pennil C; Garcia R; Goff BA; Hanash SM; Swisher EM
    Int J Gynecol Cancer; 2012 May; 22(4):546-52. PubMed ID: 22315094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Single nucleotide polymorphisms in cell cycle regulator p21 and p27 genes are associated with susceptibility to epithelial ovarian cancer].
    Jin X; Kang S; Wang N; Xing YP; Li Y
    Zhonghua Fu Chan Ke Za Zhi; 2008 Mar; 43(3):209-12. PubMed ID: 18788572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between single nucleotide polymorphisms (SNPs) of XRCC2 and XRCC3 homologous recombination repair genes and ovarian cancer in Polish women.
    Michalska MM; Samulak D; Romanowicz H; Jabłoński F; Smolarz B
    Exp Mol Pathol; 2016 Apr; 100(2):243-7. PubMed ID: 26801223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study.
    Sebastian M; Passlick B; Friccius-Quecke H; Jäger M; Lindhofer H; Kanniess F; Wiewrodt R; Thiel E; Buhl R; Schmittel A
    Cancer Immunol Immunother; 2007 Oct; 56(10):1637-44. PubMed ID: 17410361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EpCAM, a potential therapeutic target for esophageal squamous cell carcinoma.
    Matsuda T; Takeuchi H; Matsuda S; Hiraiwa K; Miyasho T; Okamoto M; Kawasako K; Nakamura R; Takahashi T; Wada N; Kawakubo H; Saikawa Y; Omori T; Kitagawa Y
    Ann Surg Oncol; 2014 Jun; 21 Suppl 3():S356-64. PubMed ID: 24566863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An investigation of relationships between hypoxia-inducible factor-1 alpha gene polymorphisms and ovarian, cervical and endometrial cancers.
    Konac E; Onen HI; Metindir J; Alp E; Biri AA; Ekmekci A
    Cancer Detect Prev; 2007; 31(2):102-9. PubMed ID: 17418979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EpCAM-autoantibody levels in the course of disease of ovarian cancer patients.
    Heubner M; Errico D; Kasimir-Bauer S; Herlyn D; Kimmig R; Wimberger P
    Med Oncol; 2011 Jun; 28(2):626-30. PubMed ID: 20383668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Association of three single nucleotide polymorphisms of the E-cadherin gene with susceptibility to epithelial ovarian carcinoma].
    Liang J; Li Y; Wang N
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Apr; 25(2):183-6. PubMed ID: 18393242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.
    Burges A; Wimberger P; Kümper C; Gorbounova V; Sommer H; Schmalfeldt B; Pfisterer J; Lichinitser M; Makhson A; Moiseyenko V; Lahr A; Schulze E; Jäger M; Ströhlein MA; Heiss MM; Gottwald T; Lindhofer H; Kimmig R
    Clin Cancer Res; 2007 Jul; 13(13):3899-905. PubMed ID: 17606723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy.
    Seimetz D; Lindhofer H; Bokemeyer C
    Cancer Treat Rev; 2010 Oct; 36(6):458-67. PubMed ID: 20347527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer.
    Fleming ND; Agadjanian H; Nassanian H; Miller CW; Orsulic S; Karlan BY; Walsh CS
    Cancer; 2012 Feb; 118(3):689-97. PubMed ID: 21751198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of epithelial cell adhesion molecule expression in the algorithmic approach to Lynch syndrome identification.
    Musulen E; Blanco I; Carrato C; Fernandez-Figueras MT; Pineda M; Capella G; Ariza A
    Hum Pathol; 2013 Mar; 44(3):412-6. PubMed ID: 23026194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.